Perineural Therapy Comprehensive Study by Type (Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Brain Stimulation}, External Neurostimulation Devices {TENS, TMS, RES}, Biomaterials {Nerve Conduits, Nerve Wraps}), End User (Hospitals and Clinics, Ambulatory Surgical Centers Market, Others) Players and Region - Global Market Outlook to 2027

Perineural Therapy Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Perineural Therapy’s another name is Neural Prolotherapy. A nerve cell needs several nutrients to keep it healthy. Perineural Therapy mainly comprises of the injecting of a dextrose (Glucose) into the body. This natural irritant when injected into the body help body with the treats the entire muscular-neuro-vascular bundle. Perineural Therapy treats inflammation and injury by feeding and hydrating the injured nerve.

Market Drivers
  • Rising prevalence of chronic pain among adults

Market Trend
  • Growing Technological Advancements in the Healthcare Industry

Restraints
  • Side Effects associated by Perineural Therapy

Opportunities
Development of Healthcare Infrastructure and Increasing Patients of Diabetes

Players Covered in the Study are:
AxoGen, Inc. (United States), Soterix Medical, Inc. (United Sates), Nevro Corp (United States), Synapse Biomedical, Inc. (United States), Baxter International, Inc. (United States), LivaNova, PLC. (United Kingdom), Integra LifeSciences (United States), Polyganics (Netherlands), NeuroPace, Inc. (United States), Aleva Neurotherapeutics (Switzerland), Collagen Matrix, Inc. (United States) and KeriMedical (Switzerland)

The Global Perineural Therapy market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

What can be explored with Perineural Therapy study:
• Where Perineural Therapy industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments

Available Customization:
List of players that can be included in the study on immediate basis are Medtronic, PLC. (Ireland), Boston Scientific Corporation (United States) and Abbott Laboratories (United States).


Report Objectives / Segmentation Covered

By Type
  • Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Brain Stimulation}
  • External Neurostimulation Devices {TENS, TMS, RES}
  • Biomaterials {Nerve Conduits, Nerve Wraps}
By End User
  • Hospitals and Clinics
  • Ambulatory Surgical Centers Market
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of chronic pain among adults
    • 3.3. Market Challenges
      • 3.3.1. Problems Associated in treating migraine headaches
    • 3.4. Market Trends
      • 3.4.1. Growing Technological Advancements in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Perineural Therapy, by Type, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Perineural Therapy (Value)
      • 5.2.1. Global Perineural Therapy by: Type (Value)
        • 5.2.1.1. Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Brain Stimulation}
        • 5.2.1.2. External Neurostimulation Devices {TENS, TMS, RES}
        • 5.2.1.3. Biomaterials {Nerve Conduits, Nerve Wraps}
      • 5.2.2. Global Perineural Therapy by: End User (Value)
        • 5.2.2.1. Hospitals and Clinics
        • 5.2.2.2. Ambulatory Surgical Centers Market
        • 5.2.2.3. Others
      • 5.2.3. Global Perineural Therapy Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Perineural Therapy (Price)
      • 5.3.1. Global Perineural Therapy by: Type (Price)
  • 6. Perineural Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AxoGen, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Soterix Medical, Inc. (United Sates)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nevro Corp (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Synapse Biomedical, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Baxter International, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LivaNova, PLC. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Integra LifeSciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Polyganics (Netherlands)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NeuroPace, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aleva Neurotherapeutics (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Collagen Matrix, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. KeriMedical (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Perineural Therapy Sale, by Type, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Perineural Therapy (Value)
      • 7.2.1. Global Perineural Therapy by: Type (Value)
        • 7.2.1.1. Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Brain Stimulation}
        • 7.2.1.2. External Neurostimulation Devices {TENS, TMS, RES}
        • 7.2.1.3. Biomaterials {Nerve Conduits, Nerve Wraps}
      • 7.2.2. Global Perineural Therapy by: End User (Value)
        • 7.2.2.1. Hospitals and Clinics
        • 7.2.2.2. Ambulatory Surgical Centers Market
        • 7.2.2.3. Others
      • 7.2.3. Global Perineural Therapy Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Perineural Therapy (Price)
      • 7.3.1. Global Perineural Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Perineural Therapy: by Type(USD Million)
  • Table 2. Perineural Therapy Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Brain Stimulation} , by Region USD Million (2016-2021)
  • Table 3. Perineural Therapy External Neurostimulation Devices {TENS, TMS, RES} , by Region USD Million (2016-2021)
  • Table 4. Perineural Therapy Biomaterials {Nerve Conduits, Nerve Wraps} , by Region USD Million (2016-2021)
  • Table 5. Perineural Therapy: by End User(USD Million)
  • Table 6. Perineural Therapy Hospitals and Clinics , by Region USD Million (2016-2021)
  • Table 7. Perineural Therapy Ambulatory Surgical Centers Market , by Region USD Million (2016-2021)
  • Table 8. Perineural Therapy Others , by Region USD Million (2016-2021)
  • Table 9. South America Perineural Therapy, by Country USD Million (2016-2021)
  • Table 10. South America Perineural Therapy, by Type USD Million (2016-2021)
  • Table 11. South America Perineural Therapy, by End User USD Million (2016-2021)
  • Table 12. Brazil Perineural Therapy, by Type USD Million (2016-2021)
  • Table 13. Brazil Perineural Therapy, by End User USD Million (2016-2021)
  • Table 14. Argentina Perineural Therapy, by Type USD Million (2016-2021)
  • Table 15. Argentina Perineural Therapy, by End User USD Million (2016-2021)
  • Table 16. Rest of South America Perineural Therapy, by Type USD Million (2016-2021)
  • Table 17. Rest of South America Perineural Therapy, by End User USD Million (2016-2021)
  • Table 18. Asia Pacific Perineural Therapy, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific Perineural Therapy, by Type USD Million (2016-2021)
  • Table 20. Asia Pacific Perineural Therapy, by End User USD Million (2016-2021)
  • Table 21. China Perineural Therapy, by Type USD Million (2016-2021)
  • Table 22. China Perineural Therapy, by End User USD Million (2016-2021)
  • Table 23. Japan Perineural Therapy, by Type USD Million (2016-2021)
  • Table 24. Japan Perineural Therapy, by End User USD Million (2016-2021)
  • Table 25. India Perineural Therapy, by Type USD Million (2016-2021)
  • Table 26. India Perineural Therapy, by End User USD Million (2016-2021)
  • Table 27. South Korea Perineural Therapy, by Type USD Million (2016-2021)
  • Table 28. South Korea Perineural Therapy, by End User USD Million (2016-2021)
  • Table 29. Australia Perineural Therapy, by Type USD Million (2016-2021)
  • Table 30. Australia Perineural Therapy, by End User USD Million (2016-2021)
  • Table 31. Rest of Asia-Pacific Perineural Therapy, by Type USD Million (2016-2021)
  • Table 32. Rest of Asia-Pacific Perineural Therapy, by End User USD Million (2016-2021)
  • Table 33. Europe Perineural Therapy, by Country USD Million (2016-2021)
  • Table 34. Europe Perineural Therapy, by Type USD Million (2016-2021)
  • Table 35. Europe Perineural Therapy, by End User USD Million (2016-2021)
  • Table 36. Germany Perineural Therapy, by Type USD Million (2016-2021)
  • Table 37. Germany Perineural Therapy, by End User USD Million (2016-2021)
  • Table 38. France Perineural Therapy, by Type USD Million (2016-2021)
  • Table 39. France Perineural Therapy, by End User USD Million (2016-2021)
  • Table 40. Italy Perineural Therapy, by Type USD Million (2016-2021)
  • Table 41. Italy Perineural Therapy, by End User USD Million (2016-2021)
  • Table 42. United Kingdom Perineural Therapy, by Type USD Million (2016-2021)
  • Table 43. United Kingdom Perineural Therapy, by End User USD Million (2016-2021)
  • Table 44. Netherlands Perineural Therapy, by Type USD Million (2016-2021)
  • Table 45. Netherlands Perineural Therapy, by End User USD Million (2016-2021)
  • Table 46. Rest of Europe Perineural Therapy, by Type USD Million (2016-2021)
  • Table 47. Rest of Europe Perineural Therapy, by End User USD Million (2016-2021)
  • Table 48. MEA Perineural Therapy, by Country USD Million (2016-2021)
  • Table 49. MEA Perineural Therapy, by Type USD Million (2016-2021)
  • Table 50. MEA Perineural Therapy, by End User USD Million (2016-2021)
  • Table 51. Middle East Perineural Therapy, by Type USD Million (2016-2021)
  • Table 52. Middle East Perineural Therapy, by End User USD Million (2016-2021)
  • Table 53. Africa Perineural Therapy, by Type USD Million (2016-2021)
  • Table 54. Africa Perineural Therapy, by End User USD Million (2016-2021)
  • Table 55. North America Perineural Therapy, by Country USD Million (2016-2021)
  • Table 56. North America Perineural Therapy, by Type USD Million (2016-2021)
  • Table 57. North America Perineural Therapy, by End User USD Million (2016-2021)
  • Table 58. United States Perineural Therapy, by Type USD Million (2016-2021)
  • Table 59. United States Perineural Therapy, by End User USD Million (2016-2021)
  • Table 60. Canada Perineural Therapy, by Type USD Million (2016-2021)
  • Table 61. Canada Perineural Therapy, by End User USD Million (2016-2021)
  • Table 62. Mexico Perineural Therapy, by Type USD Million (2016-2021)
  • Table 63. Mexico Perineural Therapy, by End User USD Million (2016-2021)
  • Table 64. Perineural Therapy: by Type(USD/Units)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Perineural Therapy: by Type(USD Million)
  • Table 78. Perineural Therapy Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Brain Stimulation} , by Region USD Million (2022-2027)
  • Table 79. Perineural Therapy External Neurostimulation Devices {TENS, TMS, RES} , by Region USD Million (2022-2027)
  • Table 80. Perineural Therapy Biomaterials {Nerve Conduits, Nerve Wraps} , by Region USD Million (2022-2027)
  • Table 81. Perineural Therapy: by End User(USD Million)
  • Table 82. Perineural Therapy Hospitals and Clinics , by Region USD Million (2022-2027)
  • Table 83. Perineural Therapy Ambulatory Surgical Centers Market , by Region USD Million (2022-2027)
  • Table 84. Perineural Therapy Others , by Region USD Million (2022-2027)
  • Table 85. South America Perineural Therapy, by Country USD Million (2022-2027)
  • Table 86. South America Perineural Therapy, by Type USD Million (2022-2027)
  • Table 87. South America Perineural Therapy, by End User USD Million (2022-2027)
  • Table 88. Brazil Perineural Therapy, by Type USD Million (2022-2027)
  • Table 89. Brazil Perineural Therapy, by End User USD Million (2022-2027)
  • Table 90. Argentina Perineural Therapy, by Type USD Million (2022-2027)
  • Table 91. Argentina Perineural Therapy, by End User USD Million (2022-2027)
  • Table 92. Rest of South America Perineural Therapy, by Type USD Million (2022-2027)
  • Table 93. Rest of South America Perineural Therapy, by End User USD Million (2022-2027)
  • Table 94. Asia Pacific Perineural Therapy, by Country USD Million (2022-2027)
  • Table 95. Asia Pacific Perineural Therapy, by Type USD Million (2022-2027)
  • Table 96. Asia Pacific Perineural Therapy, by End User USD Million (2022-2027)
  • Table 97. China Perineural Therapy, by Type USD Million (2022-2027)
  • Table 98. China Perineural Therapy, by End User USD Million (2022-2027)
  • Table 99. Japan Perineural Therapy, by Type USD Million (2022-2027)
  • Table 100. Japan Perineural Therapy, by End User USD Million (2022-2027)
  • Table 101. India Perineural Therapy, by Type USD Million (2022-2027)
  • Table 102. India Perineural Therapy, by End User USD Million (2022-2027)
  • Table 103. South Korea Perineural Therapy, by Type USD Million (2022-2027)
  • Table 104. South Korea Perineural Therapy, by End User USD Million (2022-2027)
  • Table 105. Australia Perineural Therapy, by Type USD Million (2022-2027)
  • Table 106. Australia Perineural Therapy, by End User USD Million (2022-2027)
  • Table 107. Rest of Asia-Pacific Perineural Therapy, by Type USD Million (2022-2027)
  • Table 108. Rest of Asia-Pacific Perineural Therapy, by End User USD Million (2022-2027)
  • Table 109. Europe Perineural Therapy, by Country USD Million (2022-2027)
  • Table 110. Europe Perineural Therapy, by Type USD Million (2022-2027)
  • Table 111. Europe Perineural Therapy, by End User USD Million (2022-2027)
  • Table 112. Germany Perineural Therapy, by Type USD Million (2022-2027)
  • Table 113. Germany Perineural Therapy, by End User USD Million (2022-2027)
  • Table 114. France Perineural Therapy, by Type USD Million (2022-2027)
  • Table 115. France Perineural Therapy, by End User USD Million (2022-2027)
  • Table 116. Italy Perineural Therapy, by Type USD Million (2022-2027)
  • Table 117. Italy Perineural Therapy, by End User USD Million (2022-2027)
  • Table 118. United Kingdom Perineural Therapy, by Type USD Million (2022-2027)
  • Table 119. United Kingdom Perineural Therapy, by End User USD Million (2022-2027)
  • Table 120. Netherlands Perineural Therapy, by Type USD Million (2022-2027)
  • Table 121. Netherlands Perineural Therapy, by End User USD Million (2022-2027)
  • Table 122. Rest of Europe Perineural Therapy, by Type USD Million (2022-2027)
  • Table 123. Rest of Europe Perineural Therapy, by End User USD Million (2022-2027)
  • Table 124. MEA Perineural Therapy, by Country USD Million (2022-2027)
  • Table 125. MEA Perineural Therapy, by Type USD Million (2022-2027)
  • Table 126. MEA Perineural Therapy, by End User USD Million (2022-2027)
  • Table 127. Middle East Perineural Therapy, by Type USD Million (2022-2027)
  • Table 128. Middle East Perineural Therapy, by End User USD Million (2022-2027)
  • Table 129. Africa Perineural Therapy, by Type USD Million (2022-2027)
  • Table 130. Africa Perineural Therapy, by End User USD Million (2022-2027)
  • Table 131. North America Perineural Therapy, by Country USD Million (2022-2027)
  • Table 132. North America Perineural Therapy, by Type USD Million (2022-2027)
  • Table 133. North America Perineural Therapy, by End User USD Million (2022-2027)
  • Table 134. United States Perineural Therapy, by Type USD Million (2022-2027)
  • Table 135. United States Perineural Therapy, by End User USD Million (2022-2027)
  • Table 136. Canada Perineural Therapy, by Type USD Million (2022-2027)
  • Table 137. Canada Perineural Therapy, by End User USD Million (2022-2027)
  • Table 138. Mexico Perineural Therapy, by Type USD Million (2022-2027)
  • Table 139. Mexico Perineural Therapy, by End User USD Million (2022-2027)
  • Table 140. Perineural Therapy: by Type(USD/Units)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Perineural Therapy: by Type USD Million (2016-2021)
  • Figure 5. Global Perineural Therapy: by End User USD Million (2016-2021)
  • Figure 6. South America Perineural Therapy Share (%), by Country
  • Figure 7. Asia Pacific Perineural Therapy Share (%), by Country
  • Figure 8. Europe Perineural Therapy Share (%), by Country
  • Figure 9. MEA Perineural Therapy Share (%), by Country
  • Figure 10. North America Perineural Therapy Share (%), by Country
  • Figure 11. Global Perineural Therapy: by Type USD/Units (2016-2021)
  • Figure 12. Global Perineural Therapy share by Players 2021 (%)
  • Figure 13. Global Perineural Therapy share by Players (Top 3) 2021(%)
  • Figure 14. Global Perineural Therapy share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AxoGen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. AxoGen, Inc. (United States) Revenue: by Geography 2021
  • Figure 18. Soterix Medical, Inc. (United Sates) Revenue, Net Income and Gross profit
  • Figure 19. Soterix Medical, Inc. (United Sates) Revenue: by Geography 2021
  • Figure 20. Nevro Corp (United States) Revenue, Net Income and Gross profit
  • Figure 21. Nevro Corp (United States) Revenue: by Geography 2021
  • Figure 22. Synapse Biomedical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Synapse Biomedical, Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Baxter International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Baxter International, Inc. (United States) Revenue: by Geography 2021
  • Figure 26. LivaNova, PLC. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. LivaNova, PLC. (United Kingdom) Revenue: by Geography 2021
  • Figure 28. Integra LifeSciences (United States) Revenue, Net Income and Gross profit
  • Figure 29. Integra LifeSciences (United States) Revenue: by Geography 2021
  • Figure 30. Polyganics (Netherlands) Revenue, Net Income and Gross profit
  • Figure 31. Polyganics (Netherlands) Revenue: by Geography 2021
  • Figure 32. NeuroPace, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. NeuroPace, Inc. (United States) Revenue: by Geography 2021
  • Figure 34. Aleva Neurotherapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Aleva Neurotherapeutics (Switzerland) Revenue: by Geography 2021
  • Figure 36. Collagen Matrix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Collagen Matrix, Inc. (United States) Revenue: by Geography 2021
  • Figure 38. KeriMedical (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. KeriMedical (Switzerland) Revenue: by Geography 2021
  • Figure 40. Global Perineural Therapy: by Type USD Million (2022-2027)
  • Figure 41. Global Perineural Therapy: by End User USD Million (2022-2027)
  • Figure 42. South America Perineural Therapy Share (%), by Country
  • Figure 43. Asia Pacific Perineural Therapy Share (%), by Country
  • Figure 44. Europe Perineural Therapy Share (%), by Country
  • Figure 45. MEA Perineural Therapy Share (%), by Country
  • Figure 46. North America Perineural Therapy Share (%), by Country
  • Figure 47. Global Perineural Therapy: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • AxoGen, Inc. (United States)
  • Soterix Medical, Inc. (United Sates)
  • Nevro Corp (United States)
  • Synapse Biomedical, Inc. (United States)
  • Baxter International, Inc. (United States)
  • LivaNova, PLC. (United Kingdom)
  • Integra LifeSciences (United States)
  • Polyganics (Netherlands)
  • NeuroPace, Inc. (United States)
  • Aleva Neurotherapeutics (Switzerland)
  • Collagen Matrix, Inc. (United States)
  • KeriMedical (Switzerland)
Additional players considered in the study are as follows:
Medtronic, PLC. (Ireland) , Boston Scientific Corporation (United States) , Abbott Laboratories (United States)
Select User Access Type

Key Highlights of Report


Feb 2022 206 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Perineural Therapy market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global Perineural Therapy market are AxoGen, Inc. (United States), Soterix Medical, Inc. (United Sates), Nevro Corp (United States), Synapse Biomedical, Inc. (United States), Baxter International, Inc. (United States), LivaNova, PLC. (United Kingdom), Integra LifeSciences (United States), Polyganics (Netherlands), NeuroPace, Inc. (United States), Aleva Neurotherapeutics (Switzerland), Collagen Matrix, Inc. (United States) and KeriMedical (Switzerland), to name a few.
"Growing Technological Advancements in the Healthcare Industry" is seen as one of major influencing trends for Perineural Therapy Market during projected period 2021-2027.

Know More About Global Perineural Therapy Market Report?